Sun Pharma - Sezaby To Strengthen U.S. Specialty Portfolio: Systematix
SPARC has received U.S. FDA approval for Sezaby (phenobarbital sodium) for the treatment of neonatal seizures.
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Systematix Research Report
Sun Pharma Advanced Research Company has received U.S. Food and Drug Administration approval for Sezaby (phenobarbital sodium) for the treatment of neonatal seizures.
The drug is the first and only product approved for treating seizures in neonatal patients. The product is a benzyl alcohol-free and propylene glycol-free formulation of phenobarbital sodium powder for injection.
It was granted an orphan drug designation by the U.S. FDA for the treatment of neonatal seizures and would receive seven years exclusivity.
Sun Pharmaceutical Industries Ltd. which has commercial marketing rights, expects to launch Sezaby in the U.S. in Q4 FY23. We believe this can be a $60-100 million peak sales opportunity for SPARC/Sun Pharma.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.